Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 77

1.

A review of oral toxicity associated with mTOR inhibitor therapy in cancer patients.

Martins F, de Oliveira MA, Wang Q, Sonis S, Gallottini M, George S, Treister N.

Oral Oncol. 2013 Apr;49(4):293-8. doi: 10.1016/j.oraloncology.2012.11.008. Epub 2013 Jan 9. Review.

PMID:
23312237
2.

Mammalian target of rapamycin inhibitor-associated stomatitis.

Boers-Doets CB, Raber-Durlacher JE, Treister NS, Epstein JB, Arends AB, Wiersma DR, Lalla RV, Logan RM, van Erp NP, Gelderblom H.

Future Oncol. 2013 Dec;9(12):1883-92. doi: 10.2217/fon.13.141. Review.

3.

Clinical presentation and management of mTOR inhibitor-associated stomatitis.

de Oliveira MA, Martins E Martins F, Wang Q, Sonis S, Demetri G, George S, Butrynski J, Treister NS.

Oral Oncol. 2011 Oct;47(10):998-1003. doi: 10.1016/j.oraloncology.2011.08.009. Epub 2011 Sep 3.

PMID:
21890398
4.

Incidence and risk of high-grade stomatitis with mTOR inhibitors in cancer patients.

Shameem R, Lacouture M, Wu S.

Cancer Invest. 2015 Mar;33(3):70-7. doi: 10.3109/07357907.2014.1001893. Epub 2015 Jan 30.

PMID:
25635371
5.

Preliminary characterization of oral lesions associated with inhibitors of mammalian target of rapamycin in cancer patients.

Sonis S, Treister N, Chawla S, Demetri G, Haluska F.

Cancer. 2010 Jan 1;116(1):210-5. doi: 10.1002/cncr.24696.

6.

Phase I and pharmacokinetic study of capecitabine and the oral mTOR inhibitor everolimus in patients with advanced solid malignancies.

Deenen MJ, Klümpen HJ, Richel DJ, Sparidans RW, Weterman MJ, Beijnen JH, Schellens JH, Wilmink JW.

Invest New Drugs. 2012 Aug;30(4):1557-65. doi: 10.1007/s10637-011-9723-4. Epub 2011 Aug 2.

7.

Managing stomatitis in patients treated with Mammalian target of rapamycin inhibitors.

Pilotte AP, Hohos MB, Polson KM, Huftalen TM, Treister N.

Clin J Oncol Nurs. 2011 Oct;15(5):E83-9. doi: 10.1188/11.CJON.E83-E89. Review.

PMID:
21951751
8.

[Toxicity management for mTOR inhibitors].

Mukohara T.

Nihon Rinsho. 2015 Feb;73 Suppl 2:272-6. Japanese. No abstract available.

PMID:
25831766
9.

Common occurrence of everolimus-associated aphthous stomatitis in Japanese heart transplant recipients.

Sasaoka T, Kato TS, Oda N, Wada K, Komamura K, Asakura M, Hashimura K, Ishibashi-Ueda H, Nakatani T, Isobe M, Kitakaze M.

Transplant Proc. 2010 Nov;42(9):3700-3. doi: 10.1016/j.transproceed.2010.06.023.

PMID:
21094841
10.

Cutaneous and mucosal aphthosis during temsirolimus therapy for advanced renal cell carcinoma: review of cutaneous and mucosal side effects of mTOR inhibitors.

De Masson A, Fouchard N, Méry-Bossard L, Dauendorffer JN.

Dermatology. 2011;223(1):4-8. doi: 10.1159/000329902. Epub 2011 Aug 16. Review.

PMID:
21846963
11.

Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors.

Quek R, Wang Q, Morgan JA, Shapiro GI, Butrynski JE, Ramaiya N, Huftalen T, Jederlinic N, Manola J, Wagner AJ, Demetri GD, George S.

Clin Cancer Res. 2011 Feb 15;17(4):871-9. doi: 10.1158/1078-0432.CCR-10-2621. Epub 2010 Dec 22.

12.

Strategies for the management of adverse events associated with mTOR inhibitors.

Kaplan B, Qazi Y, Wellen JR.

Transplant Rev (Orlando). 2014 Jul;28(3):126-33. doi: 10.1016/j.trre.2014.03.002. Epub 2014 Mar 12. Review.

13.

Ridaforolimus: a promising drug in the treatment of soft-tissue sarcoma and other malignancies.

Dancey JE, Monzon J.

Future Oncol. 2011 Jul;7(7):827-39. doi: 10.2217/fon.11.57. Review.

PMID:
21732754
14.

Targeted therapy for advanced renal cell cancer (RCC): a Cochrane systematic review of published randomised trials.

Coppin C, Kollmannsberger C, Le L, Porzsolt F, Wilt TJ.

BJU Int. 2011 Nov;108(10):1556-63. doi: 10.1111/j.1464-410X.2011.10629.x. Epub 2011 Sep 27. Review.

15.

[Use of mTOR-inhibitors in solid tumors].

Seidel C, Grünwald V.

Med Monatsschr Pharm. 2011 Apr;34(4):116-26; quiz 127-8. Review. German.

PMID:
21528529
16.

Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors.

Gandhi L, Bahleda R, Tolaney SM, Kwak EL, Cleary JM, Pandya SS, Hollebecque A, Abbas R, Ananthakrishnan R, Berkenblit A, Krygowski M, Liang Y, Turnbull KW, Shapiro GI, Soria JC.

J Clin Oncol. 2014 Jan 10;32(2):68-75. doi: 10.1200/JCO.2012.47.2787. Epub 2013 Dec 9.

PMID:
24323026
17.

Incidence and risk of treatment-related mortality with mTOR inhibitors everolimus and temsirolimus in cancer patients: a meta-analysis.

Qi WX, Huang YJ, Yao Y, Shen Z, Min DL.

PLoS One. 2013 Jun 13;8(6):e65166. doi: 10.1371/journal.pone.0065166. Print 2013.

18.

Mechanisms of mTOR inhibitor resistance in cancer therapy.

Carew JS, Kelly KR, Nawrocki ST.

Target Oncol. 2011 Mar;6(1):17-27. doi: 10.1007/s11523-011-0167-8. Epub 2011 Mar 9. Review.

PMID:
21547705
19.

Tolerability, safety and pharmacokinetics of ridaforolimus in combination with bicalutamide in patients with asymptomatic, metastatic castration-resistant prostate cancer (CRPC).

Meulenbeld HJ, de Bono JS, Tagawa ST, Whang YE, Li X, Heath KH, Zandvliet AS, Ebbinghaus SW, Hudes GR, de Wit R.

Cancer Chemother Pharmacol. 2013 Oct;72(4):909-16. doi: 10.1007/s00280-013-2250-6. Epub 2013 Aug 7.

PMID:
23921574
20.

Incidence and risk of pulmonary toxicity in patients treated with mTOR inhibitors for malignancy. A meta-analysis of published trials.

Iacovelli R, Palazzo A, Mezi S, Morano F, Naso G, Cortesi E.

Acta Oncol. 2012 Sep;51(7):873-9. doi: 10.3109/0284186X.2012.705019. Epub 2012 Aug 22.

PMID:
22909392

Supplemental Content

Support Center